Industry News

Curis said on Friday that its board of directors' independent compensation committee approved the grant of inducement stock options to purchase a total of 521,000 shares of its common stock to six new employees. The company added that each of the inducement grant has an exercise price per share equal to the closing price of its common stock on 12 September 2016, the date of grant. Subject to the new employee's continued service with the company through the..."/>
Curis awards inducement stock options to six new employees under NASDAQ Listing Rule 5635(c)(4)
AMN Healthcare Services Inc., Healthways Inc., MEDNAX Inc., and HEALTHSOUTH Corp.. These companies belong to the Healthcare sector which finished narrowly mixed in afternoon trading on Friday, September 16, 2016."/>
Research Reports Initiation on Specialized Health Services Stocks -- AMN Healthcare Services, Healthways, MEDNAX, and HEALTHSOUTH
NuVasive, Inc., a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced it has received FDA 510 clearance for the Company's market-leading MAGEC ® system to be surgically implanted using its Reline ® posterior fixation system for treating patients with severe spinal deformity conditions. The Company's MAGEC system is the only magnetically controlled..."/>
NuVasive Receives FDA 510(k) Clearance Reinforcing Comprehensive Portfolio Supporting Pediatric, Adolescent and Adult Spinal Deformity Patients
KemPharm, Inc., a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it has filed an Investigational New Drug application with the U.S. Food and Drug Administration to begin human clinical trials of KP415, the Company’ s prodrug, extended release d-threo-methylphenidate product candidate for the treatment of attention deficit hyperactivity disorder.."/>
KemPharm Files IND for KP415 for the Treatment of ADHD, An Investigational Prodrug of D-Threo-Methylphenidate
RXi Pharmaceuticals Corporation, a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today that it will present at the 16 th Annual Biotech in Europe Forum for Global Partnering and Investment Conference being held September 27-28, 2016 at the Congress Center, Basel, Switzerland. This Forum is recognized as the leading international stage for those..."/>
RXi Pharmaceuticals to Present at the 16th Annual Biotech in Europe Forum for Global Partnering and Investment Conference
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, today announced that Herriot Tabuteau, M.D., Axsome’ s Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016 at 8:30 AM Eastern Time. The conference will be held at the Sofitel New York in New York City.."/>
Axsome Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the filing of a New Drug Submission to Health Canada,..."/>
Intercept Pharmaceuticals Files New Drug Submission to Health Canada for Marketing Approval of Obeticholic Acid for the Treatment of Patients with Primary Biliary Cholangitis
Telesta Therapeutics Inc. today released its Fiscal 2016 consolidated financial statements and associated Management's Discussion and Analysis for the fiscal year ending June 30, 2016, which are now published in full on SEDAR and on the Company's website at www.telestatherapeutics.com. On August 24, 2016, Telesta announced that it has executed a binding agreement, subject to shareholder approval, to be acquired by ProMetic Life Sciences Inc...."/>
Telesta Therapeutics Publishes its Annual Financial Statements and Provides Date of Special Shareholders Meeting
Canopy Growth Corporation has entered into an agreement with Delivra Inc. to supply Canopy Growth's operating subsidiaries, including Tweed Inc. and Bedrocan Canada Inc., with cannabis-infused topical product formulations. Topical cannabis products have proven market demand but have yet to be created for the legal medical cannabis market in Canada. By teaming with Delivra, Tweed will be able to offer customers a unique product suite,..."/>
Canopy Growth and Delivra Partner to Offer Innovative Therapeutic Cannabis Products
AxoGen, Inc., a global leader in innovative surgical solutions for peripheral nerve injuries, today announced the election of Amy Wendell to its Board of Directors effective September 16, 2016. Wendell was also appointed to the Company’ s Compensation and Governance Committees. “Amy brings a wealth of proven healthcare experience in market and technology development as well as operating leadership,” commented Karen Zaderej, President and Chief..."/>
AxoGen, Inc. Appoints Amy Wendell to Board of Directors  
Telesta Therapeutics Inc. today released its Fiscal 2016 consolidated financial statements and associated Management's Discussion and Analysis for the fiscal year ending June 30, 2016, which are now published in full on SEDAR and on the Company's website at www.telestatherapeutics.com. On August 24, 2016, Telesta announced that it has executed a binding agreement, subject to shareholder approval, to be acquired by ProMetic Life..."/>
Telesta Therapeutics Publishes its Annual Financial Statements and Provides Date of Special Shareholders Meeting
Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, today announced that EORTC, the European Organisation for Research and Treatment of Cancer, is expanding its collaborative agreement with Ignyta. Under this collaboration, Ignyta will serve as a diagnostic laboratory performing fusion testing for EORTC’ s SPECTA initiative. Part of the testing will include identifying patients who harbor a gene fusion for the NTRK, ROS1 or ALK genes for..."/>
EORTC and Ignyta Expand Collaborative Agreement for Precision Medicine
Cytori Therapeutics today announced that the Company and Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services, increased the contract option originally signed in August 2014 to fund continued investigation and development of Cytori Cell Therapy™ for use in thermal burn injuries."/>
BARDA Increases Contract Option with Cytori to Advance Countermeasure Clinical Trial
Teva Pharmaceutical Industries Ltd., today announces top-line results from the exploratory Phase 2 PRIDE-HD study. This was a 52- week, dose-ranging trial of pridopidine twice daily versus placebo, in the treatment of Huntington disease."/>
Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease
Community Health Systems, Inc. announced today that the Company, with the assistance of advisors, is exploring a variety of options with financial sponsors, as well as other potential alternatives. The discussions are at a very preliminary stage and there is no timeline established for this review. There can be no certainty that the exploration will result in any kind of transaction."/>
Community Health Systems in Preliminary Discussions
BioDelivery Sciences International, Inc. announced that the company has secured three new managed care contracts for BUNAVAIL ® buccal film in plans where BUNAVAIL was previously non-formulary or in a non-preferred position. The three additional plans combined will provide BUNAVAIL potential access to nearly 200,000 prescriptions annually for buprenorphine products for opioid dependence, according to data from Symphony Health."/>
BioDelivery Sciences Announces Three New Managed Care Agreements; Further Enhancing Access to BUNAVAIL
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the European Patent Office has issued a Notice of Intention to Grant a European Patent covering safety features of the Company's vBloc ® Neurometabolic Therapy System. The intention to grant the European patent follows the granting of U.S. patent No...."/>
EnteroMedics Announces Receipt of Notice of Intention to Grant European Patent Covering Safety Features of vBloc® Therapy Strengthening Company's Neuromodulation Intellectual Property Portfolio of More than 70 Patents Worldwide
Teva Pharmaceutical Industries reported on Friday the availability of an authorised generic of Cubicin 500 mg per vial in the US. The company said Daptomycin for injection is an antibacterial drug indicated in adults for the treatment of complicated skin and skin structure infections caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus..."/>
Teva unveils approved generic antibacterial drug Cubicin (Daptomycin for Injection) in the US
Lannett Company, Inc. today announced that the U.S. Food and Drug Administration recently completed a cGMP inspection of the company's manufacturing facility in Philadelphia, as well as inspections of two facilities located in Armenia: Darmantest Laboratory, the company's pharmacokinetic subsidiary, and Firmplace, a stability laboratory with which the company has a strategic relationship. The inspections concluded with two minor..."/>
Lannett Announces Successful FDA Inspections of Three Facilities
Aerie Pharmaceuticals said on Friday that it has priced a registered underwritten public offering of USD75m of shares of its common stock at USD29.50 per share, before deducting underwriting discounts and commissions and other estimated offering expenses. This public offering was increased by USD25m over the prior anticipated offering. The company added that its new public offering is in addition to USD50m raised separately through the..."/>
Aerie Pharmaceuticals announces USD125m from two offerings
Canopy Growth Corporation today announced that all of management's nominees listed in its August 3, 2016 management information circular were elected as directors of the Corporation at Canopy Growth's September 15, 2016 annual shareholders' meeting. The detailed results of the vote for the election of directors held at the Annual Meeting are set out below. Canopy Growth also confirmed that shareholders approved the appointment of..."/>
Canopy Growth Corporation Announces Election of Directors
Vical Incorporated and Astellas Pharma Inc. today announced topline results from a randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety and efficacy of cytomegalovirus vaccine, ASP0113, versus placebo in kidney transplant patients receiving an organ from a CMV-seropositive donor. Results from the study demonstrated that the trial did not meet its primary endpoint, which was the proportion of patients having..."/>
Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary490 Articles
Information Technology486 Articles
Financials316 Articles
Industrials291 Articles
Health Care269 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.